Chemistry:IPT-803

From HandWiki

IPT-803 is a drug described as a dopamine modulator and opioid receptor antagonist which is or was under development for the treatment of Parkinson's disease.[1][2][3][4][5] It is under development by Tools4Patient.[1][2][3] The drug's exact mechanism of action is unclear, but may involve dopamine and endorphin pathways.[4] As of June 2020, it is in phase 1/2 clinical trials.[1][2][3][4] There have been no more recent developments since then.[1][2][3] The chemical structure of IPT-803 does not yet appear to have been disclosed.[1][3]

See also

  • List of investigational Parkinson's disease drugs

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "IPT 803". 23 June 2020. https://adisinsight.springer.com/drugs/800051195. 
  2. ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on IPT-803 with Synapse". 8 May 2025. https://synapse.patsnap.com/drug/14d838c31eae495194e5eb2613cc27c1. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 "IPT-803 Drug Profile". 1 January 1900. https://pryzm.ozmosi.com/product/24975. 
  4. ↑ 4.0 4.1 4.2 "Experimental Therapeutics in Parkinson's Disease: A Review". Neurologic Clinics 43 (2): 399–426. May 2025. doi:10.1016/j.ncl.2024.12.013. PMID 40185528. 
  5. ↑ A Study to Investigate a New Treatment in Patients With Parkinson's Disease. 13 June 2020. https://clinicaltrials.gov/study/NCT03407378. Retrieved 1 February 2026. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:IPT-803&oldid=4244531"